- Home
- AIN vs TSHA Comparison
AIN vs TSHA Comparison
Compare AIN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIN
- TSHA
- Stock Information
- Founded
- AIN 1895
- TSHA 2019
- Country
- AIN United States
- TSHA United States
- Employees
- AIN N/A
- TSHA N/A
- Industry
- AIN Textiles
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- AIN Consumer Discretionary
- TSHA Health Care
- Exchange
- AIN Nasdaq
- TSHA Nasdaq
- Market Cap
- AIN 1.7B
- TSHA 1.4B
- IPO Year
- AIN 1987
- TSHA 2020
- Fundamental
- Price
- AIN $47.82
- TSHA $3.84
- Analyst Decision
- AIN Hold
- TSHA Strong Buy
- Analyst Count
- AIN 4
- TSHA 9
- Target Price
- AIN $64.25
- TSHA $10.22
- AVG Volume (30 Days)
- AIN 365.9K
- TSHA 4.2M
- Earning Date
- AIN 11-05-2025
- TSHA 11-04-2025
- Dividend Yield
- AIN 2.24%
- TSHA N/A
- EPS Growth
- AIN N/A
- TSHA N/A
- EPS
- AIN N/A
- TSHA N/A
- Revenue
- AIN $1,148,512,000.00
- TSHA $6,310,000.00
- Revenue This Year
- AIN N/A
- TSHA N/A
- Revenue Next Year
- AIN $3.93
- TSHA N/A
- P/E Ratio
- AIN N/A
- TSHA N/A
- Revenue Growth
- AIN N/A
- TSHA N/A
- 52 Week Low
- AIN $47.65
- TSHA $1.05
- 52 Week High
- AIN $88.13
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- AIN 23.78
- TSHA 37.78
- Support Level
- AIN $51.15
- TSHA $3.89
- Resistance Level
- AIN $56.91
- TSHA $4.55
- Average True Range (ATR)
- AIN 2.48
- TSHA 0.39
- MACD
- AIN -0.86
- TSHA -0.19
- Stochastic Oscillator
- AIN 1.14
- TSHA 8.99
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.